- ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM
- EXPANSION OF IPSC DISCOVERY PLATFORM STRENGTHENS EVOTEC’S POSITION AS A LEADER IN INNOVATION-DRIVEN TRANSLATIONAL BIOLOGY
Hamburg, Germany, 15 July 2019: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform, one of the leading iPSC-based discovery platforms in the industry. The acquired assets include intellectual property relevant for iPSC-based phenotypic drug discovery, an existing cellular product business around iPSC-derived cells, as well as 17 strong team of stem cell biology experts operating from laboratories at the BioCampus Cologne.
The team has a proven track record of generating multiple disease-relevant cell types from iPSCs and their application in drug discovery. The combination with Evotec’s existing expertise in iPSC biology and the Company’s leading drug discovery platforms will create new opportunities for innovative biology and adds capacity for new and existing partnerships.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “IPSC is a game changing technology with broad applicability across a variety of different indications and drug discovery and development phases. Additional expertise and capacity in the iPSC space as well as a substantial partner network will allow us to further accelerate our efforts to build a world-leading iPSC translational biology platform across different disease areas. We warmly welcome our new team within the Evotec Family.”
No financial details of the transaction were disclosed.